Acumen Pharmaceuticals, Inc.
ABOSHeld by 7 specialist biotech funds
High Convergence7 funds opened new positions. Next phase2 readout (sabirnetug): Oct 2026. Short interest: 3.3% of float.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.